Download PDF
Thromb Haemost 1962; 08(01): 046-055
DOI: 10.1055/s-0038-1655411
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

A Two-Stage Assay Method for Hageman Factor Activity[*]

Sotirios G. Iatridis
1   Department of Physiology, School of Medicine, University of North Carolina, Chapel Hill, N.C.
,
John H. Ferguson
1   Department of Physiology, School of Medicine, University of North Carolina, Chapel Hill, N.C.
› Author Affiliations
Further Information

Publication History

Publication Date:
14 May 2019 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A two-stage assay method for assaying Hageman factor (HF) activity has been described. The method is based on the ability of a diluted test plasma or surface factor preparation to correct the clotting defect of a HF-deficient substrate plasma in a modified thromboplastin screening test. This method, being designed for investigating relative increase or decrease of HF activity, could also be used in a system with optimal amount of kaolin for assaying maximal HF activity.

* Aided by a USPHS Grant No. H-1510.


 

  • References

  • 1 Hicks N. D, Pitney W. R. A rapid screening test for disorders of thromboplastin generation.. Brit. J. Haemat. 1957; 3: 227
    CrossrefPubMedGoogle Scholar
  • 2 Ferguson J. H, Wilson E. G, Iatridis S. G, Rierson H. A, Johnston B. R. Enzymes and blood clotting. I. Trypsin as an accessory factor.. J. clin. Invest. 1960; 39: 1942
    CrossrefPubMedGoogle Scholar
  • 3 Johnston Jr. C. L, Ferguson J. H, O’Hanlon F. A. Surface activation of plasma clotting: a function of Hageman factor.. Proc. Soc. exp. Biol. (N. Y.) 1958; 99: 197
    CrossrefPubMedGoogle Scholar
  • 4 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test.. Nature (Lond.) 1954; 174: 880
    CrossrefPubMedGoogle Scholar
  • 5 Mertz E. T, Owen C. A. Imidazole buffer: its use in blood clotting studies.. Proc. Soc. exp. Biol. (N. Y.) 1940; 43: 204
    CrossrefPubMedGoogle Scholar
  • 6 Iatridis S. G, Ferguson J. H. Active Hageman factor: a plasma lysokinase of the human fibrinolytic system.. J. clin. Invest. 1962; 41: 1277
    CrossrefPubMedGoogle Scholar
  • 7 Nardisty R. M, Margolis J. The role of Hageman factor in the initiation of blood coagulation. Brit. J. Haemat. 1959; 5: 203
    CrossrefPubMedGoogle Scholar
  • 8 Iatridis S. G, Ferguson J. H, Rierson H. A, Robinson A. J. Effects of exercise on blood clotting and fibrinolysis.. Fed. Proc. 1962; 21: 58
    PubMedGoogle Scholar
  • 9 Ratnoff O. D, Colopy J. E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma.. J. clin. Invest. 1955; 34: 602
    CrossrefPubMedGoogle Scholar
  • 10 Rosenthal R. L, Dreskin O. H, Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency: clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease.. Blood 1955; 10: 120
    CrossrefPubMedGoogle Scholar
  • 11 Waaler B. A. Contact activation in the intrinsic blood clotting system.. Scand. J. clin. Lab. Invest. 1959; 11 Suppl. 37
    CrossrefPubMedGoogle Scholar
  • 12 Soulier J.-P, Prou-Wartelle O. New data on Hageman factor and plasma thromboplastin antecedent: the role of “contact” in the initial phase of blood coagulation.. Brit. J. Haemat. 1960; 6: 88
    CrossrefPubMedGoogle Scholar
  • 13 Ratnoff O. D, Davie E. W, Mallett D. L. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent.. J. clin. Invest. 1961; 40: 803
    CrossrefPubMedGoogle Scholar
  • 14 Margolis J. Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation.. J. Physiol. 1958; 144: 1
    PubMedGoogle Scholar